Clinical trials: Bullous Dermatoses
Bullous Pemphigoid
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).
- Trial name
- FJORD (NCT04612790)
- Testing
- Benralizumab
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 67 people
- Sponsor
- AstraZeneca
Pemphigus Vulgaris, Bullous Pemphigoid
Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
This study assesses the disinfectant and healing promoting effect of ozonated olive oil in treatment of pemphigus vulgaris and bullous pemphigoid in comparison to conventional topical treatment with topical antibiotic.
- Trial name
- NCT05594472
- Testing
- Ozonated olive oil, Topical garamycin cream
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Bullous Pemphigoid
Telederm and Bullous Pemphigoid
The purpose of the study is to improve the quality of future clinical trials in bullous pemphigoid (BP), the investigators will monitor repeated measurement data from patients with BP on standard-of-care treatments at four week…
- Trial name
- NCT04728854
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Emory University
Bullous Pemphigoid
Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis
Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease primarily affecting the elderly with a significant risk of mortality and morbidity.
- Trial name
- BP (NCT06213909)
- Testing
- This is a retrospective analysis of health data from inpatient record, no intervention was designed
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Xijing Hospital
Bullous Pemphigoid
Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
The objective of this clinical trial was to evaluate whether DF2156A has a potential in improving the clinical outcome in patients with active blistering bullous pemphigoid (BP) to warrant its further development.
- Trial name
- NCT01571895
- Testing
- DF2156A
- Where
- 4 sites in Germany, Italy
- Volunteers
- 4 people
- Sponsor
- Dompé Farmaceutici S.p.A
Bullous Emphysema
Bronchoscopic Intrabullous Autologous Blood Instillation (BIABI) for Emphysema
Patients with large bullae (large empty air sacs in the lung) may benefit from bullectomy (surgery to resect these bullae), however this is a major surgery with significant potential morbidity and long hospital stays.
- Trial name
- BIABI (NCT01727037)
- Testing
- Bronchoscopic intrabullous autologous blood instillation
- Where
- 3 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Bullous Pemphigoid (BP)
Prevalence of Sleep Disturbances in Bullous Pemphigoid Patients.
Bullous pemphigoid (BP) is the most common autoimmune blistering disorder. The incidence of BP has increased due to increased life expectancy, particularly in developed countries, which can be associated with multiple geriatric…
- Trial name
- SLEEP-BP (NCT07188402)
- Testing
- Prevalence of sleep disturbances in patients with bullous pemphigoid, Prevalence of sleep disturbances in healthy volunteers without bullous pemphigoid
- Where
- France
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid (BP)
Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate…
- Trial name
- NCT07210554
- Testing
- Stapokibart injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.
Bullous Dermatoses, Psoriasis
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
This is a randomised controlled trial conducted to prove that the immunological performance of intradermal tozinameran (i.e., Pfizer-BioNTech COVID-19 vaccine) is no worse than the standard intramuscular route in patients with…
- Conditions
- Bullous Dermatoses, Psoriasis, COVID-19 Vaccines
- Trial name
- NCT05406908
- Testing
- tozinameran
- Where
- Thailand
- Volunteers
- 109 people
- Sponsor
- Mahidol University
Bullous Pemphigoid
Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid
To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
- Trial name
- NCT00431119
- Testing
- Azathioprine or Mycophenolate mofetil
- Where
- 11 sites in Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Muenster
Periodontal Diseases, Psoriasis
Periodontal Status in Patients With Chronic Skin Diseases
Objective: This study aimed to evaluate and compare the periodontal status of chronic skin disease (CSD) patients with healthy controls. Material and method: 109 patients and 37 healthy subjects were included in this study.
- Conditions
- Periodontal Diseases, Psoriasis, Atopic Dermatitis, Autoimmune Bullous Dermatosis
- Trial name
- NCT06073613
- Testing
- oral health status
- Where
- Vietnam
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
Pemphigoid, Bullous
The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
This is an open-label, pilot study evaluating the efficacy of tildrakizumab on the treatment of bullous pemphigoid (BP) in eligible patients (see detailed study protocol).
- Trial name
- NCT04465292
- Testing
- Tildrakizumab Prefilled Syringe
- Volunteers
- 16 people
- Sponsor
- Brigham and Women's Hospital
Bullous Pemphigoid
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody".
- Trial name
- LIBERTY-BP (NCT04206553)
- Testing
- dupilumab, Oral corticosteroids (OCS)
- Where
- 53 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Regeneron Pharmaceuticals
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
: Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin.
- Conditions
- Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
- Trial name
- NCT03016715
- Testing
- Sirolimus 2%, Vehicle
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Premier Specialists, Australia
Bullous Pemphigoid
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
The development of Auto Immune bullous Diseases (AIBD) results from a complex interaction between innate and adaptive immune systems.
- Trial name
- IPH (NCT04563923)
- Testing
- Avdoralimab (IPH5401), Control
- Where
- 4 sites in France
- Volunteers
- 15 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pemphigus
Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders
Autoimmune Bullous Skin Disorders are believed to be due to immune cells, cells that normally protect the body and are now causing damage to the body.
- Trial name
- NCT00278642
- Testing
- Hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Richard Burt, MD
Pemphigoid, Bullous, Pemphigus
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
The primary objective of this study is to describe and compare plasmatic anti-proteasome auto-antibody concentrations among three distinct groups: (1) patients suffering from bullous pemphigoide; (2) patients suffering from other…
- Conditions
- Pemphigoid, Bullous, Pemphigus, Lupus Erythematosus, Cutaneous
- Trial name
- NCT01559155
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Lichen Planus, Oral
Evaluation of Desmoglein-3 Autoantibodies in the Tissues of Oral Lichen Planus and Correlation with Disease Severity
1. evaluate the level of Dsg3 autoantibodies in tissue biopsy of Atrophic/Bullous Erosive (A/BE) OLP (Primary Objective). 2. correlate the severity of the disease with the level of tissue Dsg3 autoantibodies (Secondary Objective).
- Trial name
- NCT06652477
- Testing
- ELISA
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Bullous Pemphigoid
Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid
This controlled multi-center randomized clinical trial, with direct individual benefit, will compare efficacy and safety of two strategies in non-localized BP care: a combined regimen using initial superpotent topical steroids…
- Trial name
- BP/MTX (NCT02313870)
- Testing
- clobetasol propionate + Methotrexate, clobetasol propionate alone
- Where
- France
- Volunteers
- 322 people
- Sponsor
- University Hospital, Montpellier
Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
This study investigates the genetic architecture of Neutrophil-Mediated Inflammatory Skin Diseases. After collecting informed consent, all patients' clinical phenotype is graded at inclusion with a detailed case report form and a…
- Conditions
- Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum, Erosive Pustular Dermatosis of the Scalp, Sweet's Syndrome
- Trial name
- NEUTROGENE (NCT01952275)
- Testing
- Collection of biological samples
- Where
- Switzerland
- Volunteers
- 600 people
- Sponsor
- University of Zurich